Inspira Technologies OxyIINN
IINN
About: Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Employees: 37
0
Funds holding %
of 7,315 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
18% more capital invested
Capital invested by funds: $197K [Q4 2024] → $232K (+$35.1K) [Q1 2025]
0.31% more ownership
Funds ownership: 1.05% [Q4 2024] → 1.36% (+0.31%) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
7% less funds holding
Funds holding: 14 [Q4 2024] → 13 (-1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
43%
upside
Avg. target
$2
43%
upside
High target
$2
43%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Litchfield Hills Theodore O'Neill | 43%upside $2 | Buy Initiated | 2 Jun 2025 |
Financial journalist opinion
Based on 3 articles about IINN published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100
RA'ANANA, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has successfully achieved all key strategic objectives in its high-level talks with a government health authority, located outside of the United States, on July 8, 2025, a meeting previously announced by the Company on July 7, 2025, establishing a definitive pathway for the nationwide adoption of the Company's ART100 system and creating the foundation for a future global scale-up.
Neutral
GlobeNewsWire
1 week ago
Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework
RA'ANANA, Israel, July 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system as a foundational component of the national emergency infrastructure and to establish a global distribution framework.
Neutral
GlobeNewsWire
1 week ago
Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase
RA'ANANA, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system, representing a major commercial inflection point for the Company. The order was placed by a privately held company headquartered outside the United States, in a global strategic hub, with an established track record and active commercial ties to both government entities and institutional healthcare customers.
Neutral
GlobeNewsWire
1 month ago
Inspira's ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions
RA'ANANA, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation.
Neutral
GlobeNewsWire
1 month ago
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
Neutral
GlobeNewsWire
1 month ago
Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
Neutral
GlobeNewsWire
1 month ago
Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System
Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizations Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizations
Neutral
GlobeNewsWire
2 months ago
INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients
RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures. As part of this advancement, Inspira will deploy the U.S. Food and Drug Administration (“FDA”) approved INSPIRA ART100 system at one of Israel's renowned medical centers affiliated with the largest health care provider.
Neutral
GlobeNewsWire
2 months ago
Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing
RA'ANANA, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ technology.
Neutral
GlobeNewsWire
2 months ago
Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems
The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility
Charts implemented using Lightweight Charts™